<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761683</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-ORO-ZOL-2007/1</org_study_id>
    <nct_id>NCT00761683</nct_id>
  </id_info>
  <brief_title>Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS</brief_title>
  <acronym>ESIS</acronym>
  <official_title>Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent
      reduction scores for symptoms: dysmenorrhoea, dyspareunia and pelvic pain; to observe the
      effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction
      scores for pelvic tenderness and indurations; to observe the reduction in the proportion of
      patients requiring analgesics for the relief of pelvic pain for 6 months in patients treated
      with Zoladex 3.6 mg.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Anticipated number of patients not achieved. All Patients recruited in the study completed all
    study visits.
  </why_stopped>
  <start_date>October 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biberoglu and Bergham Scale</measure>
    <time_frame>monthly/ at every clinic visit- 6 times for symptoms: dysmenorrhoea, dyspareunia and pelvic pain</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biberoglu and Bergham Scale</measure>
    <time_frame>twice/first and last clinic visit for pelvic tenderness and indurations</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients diagnosed with endometriosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The programme will include the patients diagnosed with endometriosis that the doctors have
        already decided to treat with Zoladex within the last month, before inclusion in this
        program.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with endometriosis that the doctors have already decided to treat
             with Zoladex within the last month, before inclusion in this program, according to
             Romanian approved goserelin 3,6 mg

        Exclusion Criteria:

          -  patients who have a known hypersensitivity to goserelin (Zoladex) or any of its
             excipients or any other GnRH analogue, pregnancy, according to Romanian approved
             goserelin 3,6 mg SmPC
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Pentiuc</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Cristina Pentiuc Medical Manager</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

